vs
CoreCivic, Inc.（CXW）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是CoreCivic, Inc.的1.3倍（$772.1M vs $604.0M），Revvity净利率更高（12.7% vs 4.4%，领先8.3%），CoreCivic, Inc.同比增速更快（26.0% vs 5.9%），Revvity自由现金流更多（$161.8M vs $-45.1M），过去两年CoreCivic, Inc.的营收复合增速更高（9.8% vs 9.0%）
CoreCivic, Inc.是美国私营监狱运营企业，为美国规模最大的营利性监狱、看守所及拘留设施承包商之一。该公司在美国运营70余座州级及联邦惩教、拘留场所，曾因相关场所被指存在民权侵犯、强迫劳动问题，成为撤资运动针对对象，还遭到FBI调查及多起诉讼。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CXW vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.3倍
$604.0M
营收增速更快
CXW
高出20.2%
5.9%
净利率更高
RVTY
高出8.3%
4.4%
自由现金流更多
RVTY
多$206.9M
$-45.1M
两年增速更快
CXW
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $604.0M | $772.1M |
| 净利润 | $26.5M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 6.0% | 14.5% |
| 净利率 | 4.4% | 12.7% |
| 营收同比 | 26.0% | 5.9% |
| 净利润同比 | 37.7% | 3.9% |
| 每股收益（稀释后） | $0.26 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CXWRVTY
| Q4 25 | $604.0M | $772.1M | ||
| Q3 25 | $580.4M | $698.9M | ||
| Q2 25 | $538.2M | $720.3M | ||
| Q1 25 | $488.6M | $664.8M | ||
| Q4 24 | $479.3M | $729.4M | ||
| Q3 24 | $491.6M | $684.0M | ||
| Q2 24 | $490.1M | $691.7M | ||
| Q1 24 | $500.7M | $649.9M |
净利润CXWRVTY
| Q4 25 | $26.5M | $98.4M | ||
| Q3 25 | $26.3M | $46.7M | ||
| Q2 25 | $38.5M | $53.9M | ||
| Q1 25 | $25.1M | $42.2M | ||
| Q4 24 | $19.3M | $94.6M | ||
| Q3 24 | $21.1M | $94.4M | ||
| Q2 24 | $19.0M | $55.4M | ||
| Q1 24 | $9.5M | $26.0M |
毛利率CXWRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率CXWRVTY
| Q4 25 | 6.0% | 14.5% | ||
| Q3 25 | 6.3% | 11.7% | ||
| Q2 25 | 9.7% | 12.6% | ||
| Q1 25 | 6.6% | 10.9% | ||
| Q4 24 | 5.2% | 16.3% | ||
| Q3 24 | 6.1% | 14.3% | ||
| Q2 24 | 5.6% | 12.4% | ||
| Q1 24 | 1.8% | 6.8% |
净利率CXWRVTY
| Q4 25 | 4.4% | 12.7% | ||
| Q3 25 | 4.5% | 6.7% | ||
| Q2 25 | 7.2% | 7.5% | ||
| Q1 25 | 5.1% | 6.4% | ||
| Q4 24 | 4.0% | 13.0% | ||
| Q3 24 | 4.3% | 13.8% | ||
| Q2 24 | 3.9% | 8.0% | ||
| Q1 24 | 1.9% | 4.0% |
每股收益（稀释后）CXWRVTY
| Q4 25 | $0.26 | $0.86 | ||
| Q3 25 | $0.24 | $0.40 | ||
| Q2 25 | $0.35 | $0.46 | ||
| Q1 25 | $0.23 | $0.35 | ||
| Q4 24 | $0.18 | $0.77 | ||
| Q3 24 | $0.19 | $0.77 | ||
| Q2 24 | $0.17 | $0.45 | ||
| Q1 24 | $0.08 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.9M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.4B | $7.3B |
| 总资产 | $3.3B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CXWRVTY
| Q4 25 | $97.9M | $919.9M | ||
| Q3 25 | $56.6M | $931.4M | ||
| Q2 25 | $130.5M | $991.8M | ||
| Q1 25 | $74.5M | $1.1B | ||
| Q4 24 | $107.5M | $1.2B | ||
| Q3 24 | $107.8M | $1.2B | ||
| Q2 24 | $60.2M | $2.0B | ||
| Q1 24 | $111.4M | $1.7B |
股东权益CXWRVTY
| Q4 25 | $1.4B | $7.3B | ||
| Q3 25 | $1.5B | $7.4B | ||
| Q2 25 | $1.5B | $7.6B | ||
| Q1 25 | $1.5B | $7.6B | ||
| Q4 24 | $1.5B | $7.7B | ||
| Q3 24 | $1.5B | $7.9B | ||
| Q2 24 | $1.4B | $7.9B | ||
| Q1 24 | $1.4B | $7.8B |
总资产CXWRVTY
| Q4 25 | $3.3B | $12.2B | ||
| Q3 25 | $3.1B | $12.1B | ||
| Q2 25 | $3.1B | $12.4B | ||
| Q1 25 | $3.0B | $12.4B | ||
| Q4 24 | $2.9B | $12.4B | ||
| Q3 24 | $2.9B | $12.8B | ||
| Q2 24 | $2.9B | $13.4B | ||
| Q1 24 | $3.0B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-376.0K | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-45.1M | $161.8M |
| 自由现金流率自由现金流/营收 | -7.5% | 21.0% |
| 资本支出强度资本支出/营收 | 7.4% | 2.6% |
| 现金转化率经营现金流/净利润 | -0.01× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $52.8M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CXWRVTY
| Q4 25 | $-376.0K | $182.0M | ||
| Q3 25 | $53.8M | $138.5M | ||
| Q2 25 | $96.7M | $134.3M | ||
| Q1 25 | $44.5M | $128.2M | ||
| Q4 24 | $39.3M | $174.2M | ||
| Q3 24 | $91.5M | $147.9M | ||
| Q2 24 | $68.1M | $158.6M | ||
| Q1 24 | $70.4M | $147.6M |
自由现金流CXWRVTY
| Q4 25 | $-45.1M | $161.8M | ||
| Q3 25 | $16.1M | $120.0M | ||
| Q2 25 | $61.9M | $115.5M | ||
| Q1 25 | $20.0M | $112.2M | ||
| Q4 24 | $16.0M | $149.8M | ||
| Q3 24 | $73.7M | $125.6M | ||
| Q2 24 | $49.3M | $136.6M | ||
| Q1 24 | $59.7M | $129.7M |
自由现金流率CXWRVTY
| Q4 25 | -7.5% | 21.0% | ||
| Q3 25 | 2.8% | 17.2% | ||
| Q2 25 | 11.5% | 16.0% | ||
| Q1 25 | 4.1% | 16.9% | ||
| Q4 24 | 3.3% | 20.5% | ||
| Q3 24 | 15.0% | 18.4% | ||
| Q2 24 | 10.1% | 19.7% | ||
| Q1 24 | 11.9% | 20.0% |
资本支出强度CXWRVTY
| Q4 25 | 7.4% | 2.6% | ||
| Q3 25 | 6.5% | 2.6% | ||
| Q2 25 | 6.5% | 2.6% | ||
| Q1 25 | 5.0% | 2.4% | ||
| Q4 24 | 4.9% | 3.4% | ||
| Q3 24 | 3.6% | 3.3% | ||
| Q2 24 | 3.8% | 3.2% | ||
| Q1 24 | 2.1% | 2.7% |
现金转化率CXWRVTY
| Q4 25 | -0.01× | 1.85× | ||
| Q3 25 | 2.04× | 2.97× | ||
| Q2 25 | 2.51× | 2.49× | ||
| Q1 25 | 1.77× | 3.03× | ||
| Q4 24 | 2.04× | 1.84× | ||
| Q3 24 | 4.34× | 1.57× | ||
| Q2 24 | 3.59× | 2.87× | ||
| Q1 24 | 7.37× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CXW
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
